Background: Interleukin (IL)-35 regulates imbalance between regulatory T cells (Tregs) and T helper (Th) 17 cells, leading to an important modulator in autoimmune disorder, cancer, and infectious diseases. Our previous study revealed an immunosuppressive activity of IL-35 in chronic hepatitis B virus (HBV) infection. Thus, the aim of the current study was to investigate the role of regulatory function of IL-35 to viral specific Tregs/Th17 cells balance in chronic HBV infection.
Background
Chronic hepatitis B virus (HBV) infection is still a large public health problem, with approximate 350 million persistent infections all over the world [1] . Chronic HBV infection always leads to end-stage liver diseases, such as decompensated cirrhosis, severe hepatitis, and hepatocellular carcinoma (HCC), resulting in more than 1 million deaths annually worldwide [2] . It is well accepted that the outcome of hepatitis B patients is closely related to the interaction between host immune system and virus itself [3] . Acute HBV infection in adults always induces multi-specific T cell-responses, which is pivotal for viral clearance and controlling the infection [4] . However, HBV infection in infants or children always results in persistent infections, which manifested as weak or undetectable cellular immune responses [5] . More importantly, the precise mechanism of T cell hyporesponsiveness and immune tolerance in chronic HBV infection is still not fully understood.
Naïve CD4 + T cells can differentiate into different T helper (Th) cells upon activation by various transcriptional factors and cytokines. CD4 + CD25 + regulatory T cells (Tregs) express high level of FoxP3 but low to absent level of CD127 [6] , and contribute to immune tolerance via direct cell contact and inhibitory cytokines [mainly interleukin (IL)-10 and IL-35] production during chronic viral infections [7] . Th17 cells express high level of transcriptional factor retinoic acid-related orphan receptor γt (RORγt) and secrete IL-17 and IL-22 [8, 9] , which induce inflammation and fibrosis in HBV infection [10, 11] . The imbalance between Tregs and Th17 cells was shown to be associated with liver injury [12] and be an indicator of liver cirrhosis process and a risk factor for HCC occurrence in patients with chronic hepatitis B (CHB) [13] . However, most of the previous reports focused on natural or non-specific Tregs/Th17 cells in chronic viral infection. Few studies revealed HBV-specific Tregs and Th17 cells imbalance during chronic HBV infection.
IL-35, which was mainly secreted by Tregs, is a newly identified IL-12 cytokine family member, and comprises two heterdimeric subunits, IL-12 α chain p35 (IL12p35) and IL-27 β chain Epstein-Barr virus-induced gene 3 (EBI3) [14, 15] . Our previous studies indicated that elevated serum IL-35 played an immunosuppressive activity and promoted inhibitory function of CD4 + CD25 + CD127 dim/− Tregs in chronic HBV and hepatitis C virus (HCV) infections [16, 17] . A recent study by Huang et al. showed that IL-35 modulated the imbalance between Tregs and Th17 cells in enterovirus 71-induced hand, foot, and mouth disease [18] . Thus, we hypothesized that IL-35 could also regulate viral specific Tregs/Th17 imbalance in chronic HBV infection. To test this possibility, we investigated circulating HBV-specific Tregs and Th17 cell population and assessed the effect of recombinant IL-35 on HBV-specific Tregs/ Th17 function in patients with chronic HBV infection.
Methods

Enrolled patients
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The protocol was approved by the Ethics Committee of The Second Hospital of Jilin University on March 2017, and written informed consent was obtained from each participant. Twenty-one of HLA-A2 restricted CHB patients and 23 of HLA-A2 restricted asymptomatic HBV carriers (ASC) were enrolled in the present study. All patients were hospitalized or followed-up in Department of Hepatopancreatobiliary Medicine Affiliated to The Second Hospital of Jilin University between July 2017 and March 2018, and diagnose was made in accordance with diagnostic standard of Chinese Guideline of Prevention and Treatment for Chronic Hepatitis B (2010 Version). All patients were positive for HBV e antigen (HBeAg), and treatmentnaïve to nucleos(t)ide analogue and interferon-α. Serum alanine aminotransferase (ALT) presented more than 2-fold elevation in CHB patients, while ALT level was normal in ASC group. No patients received immunomodulatory therapies 1 year before sampling. Patients who were co-infected with other hepatovirus or human immunodeficiency virus (HIV), or afflicted with immune disorder or malignance diseases were excluded from this study. The baseline characteristics of all enrolled patients were shown in Table 1 .
Virological and biochemical assessments
HBV DNA was quantified by a commercial real-time polymerase chain reaction (PCR)-Fluorescence Quantitative Detection Kit for HBV DNA (Da' An Gene, Guangzhou, Guangdong Province, China) with detection 
Real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen, Thermo Fisher Scientific, Carlsbad, CA, USA) according to manufacturer's instruction. cDNA was synthesized with oligo(dT) primer and random 6 mers using PrimeScript RT Master Mix (TaKaRa, Beijing, China). Real-time PCR was performed using TB Green Premix Ex Taq II (TaKaRa). The relative gene expression was quantified by 2 -ΔΔCT method using ABI7500 System Sequence Detection Software (Applied Biosystems, Foster, CA, USA). The sequences of primers were as following. FoxP3 sense: 5′-CCT CCC CCA TCA TAT CCT TT-3′; FoxP3 anti-sense: 5′-TTG GGG TTT GTG TTG AGT GA-3′; RORγt sense: 5′-AGT CGG AAG GCA AGA TCA GA-3′; RORγt anti-sense: 5′-CAA GAG AGG TTC TGG GCA AG-3′; IL-12p35 sense: 5′-TTC CCA TGC CTT CAC CAC TC-3′; IL-12p35 anti-sense: 5′-TAA ACA GGC CTC CAC TGT GC-3′; EBI3 sense: 5′-TTA CAA GCG TCA GGG AGC TG-3′; EBI3 anti-sense: 5′-TTC CCC GTA GTC TGT GAG GT-3′; GAPDH sense: 5′-GCA CCG TCA AGG CTG AGA AC-3′; GAPDH anti-sense: 5′-TGG TGA AGA CGC CAG TGG A-3′.
ELISA
Cytokine production in the supernatants were measured using commercial ELISA kits (CusaBio, Wuhan, Hubei Province, China) according to manufacturer's instruction.
Western blot
Western blot was performed as described previously [16] . Briefly, cells were lysed on ice for 5 min in 2 × SDS buffer with β-mercaptoethanol, and were treated in 95°C for 10 min. Supernatants were harvested by centrifugation for 1 min at 10,000×g. Total proteins were loaded and separated on SDS-PAGE gels, and were electroblotted onto PVDF membrane. The membrane was soaked for 2 h in block solution, and then incubated overnight in the presence of rabbit polyclonal to signal transducers and activators of transcription 3 (STAT3, phospho Y705, ab76315), or STAT3 (ab32500) (Abcam, Cambridge, MA, USA; 1: 1000 dilution). Horseradish peroxidase-conjugated goat anti-rabbit antibody IgG (Abcam; 1: 2000 dilution) was added for additional 2 h incubation. Antigen-antibody complexes were observed by enhanced chemiluminescence (Western Blotting Luminol Reagent, Cell Signaling Technology, Danvers, MA, USA).
Statistical analyses
All data were analyzed using SPSS Version 21.0 for Windows (Chicago, IL, USA). Shapiro-Wilk test was used for normal distribution assay. Variables following normal distribution were presented as mean ± standard deviation, and statistical significance was determined by Student t test or paired t test. Variables following skewed distribution were presented as median [Q1, Q3], and statistical significance was determined by Mann-Whitney test or Wilcoxon matched pairs test. All tests were two-tailed, and P value of less than 0.05 was considered to indicate significant difference.
Results
Imbalance between HBV core-specific CD4 Fig. 1b) . However, the percentage of viral specific Th17 cells in CHB was significantly higher than in ASC (0.97 ± 0.20% vs. 0.81 ± 0.13%, Student t test, P = 0.0024, Fig. 1c) . Thus, ratio of HBc specific Tregs/Th17 in CHB was notably lower in comparison with ASC (12.62 ± 3.39 vs. 15.68 ± 4.27, Student t test, P = 0.012, Fig. 1d ). + Th17 cells percentage was significantly down-regulated in ASC when compared with CHB. d Ratio of Tregs/Th17 was notably increased in ASC when compared with CHB. Individual level for each subject was presented, and comparisons were made using Student t tests elevated in both CHB and ASC [17] . It was also accepted that Tregs and other cell types (including activated myeloid, endothelial cells, regulatory B cells) could secret IL-35 [19] . Thus, IL-12p35 and EBI3 mRNA expression in unstimulated CD4 + T cells was firstly screened by real-time PCR. IL-12p35 mRNA was comparable between CHB and ASC (Student t test, P = 0.745, Fig. 2a) . However, EBI3 mRNA was significantly elevated in CD4 + T cells from CHB when compared with those from ASC (Student t test, P = 0.0009, Fig. 2b Fig. 2c ) and ASC (15.31 ± 3.20% vs. 13.64 ± 3.32%, paired t test, P = 0.025, Fig. 2c ). However, IL-35 treatment only slightly down-regulated Th17 cells frequency in CHB (1.14 ± 0.10% vs. 1.10 ± 0.14%) and ASC (0.87 ± 0.12% vs. 0.82 ± 0.15%), and those differences failed to achieve significances (paired t tests, P = 0.212 and P = 0.127, respectively, Fig. 2d ). Although ratio of Tregs/Th17 was remarkable elevated in both CHB (15.28 ± 2.98 vs. 11.35 ± 2.98, paired t test, P = 0.0003, Fig. 2e ) and ASC (19.20 ± 4.87 vs. 16.03 ± 4.76, paired t test, P = 0.021, Fig. 2e ) in response to IL-35 stimulation, this ratio was still higher in ASC in comparison with in CHB (Student t test, P = 0.0074, Fig. 2e ). mRNA relative expression corresponding to key transcriptional factor for Tregs (FoxP3) and Th17 cells (RORγt) was investigated by real-time PCR. FoxP3 mRNA was elevated in both CHB (paired t test, P < 0.0001, Fig. 2f ) and ASC (paired t test, P = 0.0076, Fig. 2f ) in response IL-35 stimulation. However, IL-35 treatment did not affect RORγt mRNA expression in CD4 + T cells from either CHB (paired t test, P = 0.949, Fig. 2g ) or ASC (paired t test, P = 0.069, Fig. 2g ). Tregs-secreting IL-10 and Th17-secreting IL-17 production in the cultured supernatants were also measured by ELISA. IL-10 expression was elevated in response to IL-35 stimulation in CHB (131. 4 Fig. 2i ). pSTAT3 and STAT3 expression in CD4 + T cells was investigated by Western blot (Fig. 2j) . STAT3 phosphorylation was significantly down-regulated in CD4 + T cells in response to IL-35 treatment, however, total STAT3 expression was comparable in the presence or absence of IL-35 stimulation (Fig. 2j) .
IL-35 stimulation reduced viral specific Th17 differentiation of Tregs in CHB
Our previous study has been demonstrated that IL-35 stimulation in vitro robustly promoted inhibitory activity of CD4 + CD25 + CD127 dim/− Tregs [17] . Th17-like phenotype could also be induced from both human naïve and effector Tregs, leading to reduced suppressive function [20, 21] Fig. 3a ) and CCR6 + percentage (4.21 ± 0.73% vs. 4.99 ± 1.00%, paired t test, P = 0.006, Fig. 3b) within Tregs was significantly reduced in response to IL-35 stimulation. IL-17 and IL-22 production by Tregs was also measured in cultured supernatants. Both IL-17 (4.12 ± 0.78 pg/mL vs. 5.10 ± 1.39 pg/mL, paired t test, P = 0.027, Fig. 3c ) and IL-22 secretion (11.88 ± 2.52 pg/mL vs. 14.74 ± 2.53 pg/mL, paired t test, P = 0.023, Fig. 3d ) was remarkably down-regulated with IL-35 stimulation.
Effective antiviral therapy reduced responsiveness of CD4 + T cells and Tregs to IL-35 stimulation in CHB
Ten of CHB patients received tenofovir disoproxil fumarate (TDF, 300 mg once daily), and all ten patients reached virological response with undetectable HBV DNA in the serum three month post-therapy. CD4 + T cells and CD4 + CD25 + CD127 dim/− Tregs were purified, and were stimulated with IL-35 in the presence of HBc 18-27 peptide for 12 h. There were no significant difference in viral specific Tregs (11.91 ± 2.49% vs. 12.43 ± 2.89%, paired t test, P = 0.415, Fig. 4a ), Th17 cells (0.85 ± 0.15% vs. 0.94 ± 0.24%, paired t test, P = 0.291, Fig. 4b ), or IL-35 expression in the serum (76.30 ± 5.27 pg/mL vs. 78.10 ± 6.44 pg/mL, paired t test, P = 0.345, Fig. 4c ) in response to TDF therapy. IL-35 stimulation in vitro did not elevated viral specific Tregs (11.75 ± 1.70% vs. 13.34 ± 2.53%, paired t test, P = 0.160, Fig. 4d ) or Th17 cells (1.17 ± 0.06% vs. 1.22 ± 0.08%, paired t test, P = 0.193, Fig. 4e ) within CD4 + T cells from TDF-treated CHB patients. Moreover, CCR4 + (1.18 ± 0.13% vs. 1.22 ± 0.27%, paired t test, P = 0.401, Fig. 4f ) and CCR6 + (4.77 ± 0.91% vs. 5.13 ± 1.23%, paired t test, P = 0.460, Fig. 4g ) cells were also did not affected by IL-35 in vitro stimulation in purified CD4 + CD25 + CD127 dim/− Tregs from TDF-treated CHB patients.
Discussion
In the present study, an increased HBV core-specific Th17 cell response was found in CHB patients, leading to the reduction of viral specific Tregs/Th17 ratio in CHB patients when compared with ASC. Recombinant + IL-17 + Th17 cells percentage was comparable between IL-35 stimulated and unstimulated CD4 + T cells in both CHB and ASC. e Ratio of Tregs/Th17 was increased in response to IL-35 stimulation in both CHB and ASC. Individual level for each subject was presented, and comparisons were made using paired t tests. mRNA relative expressions corresponding to Tregs transcriptional factor FoxP3 and Th17 transcriptional factor RORγt were measured by real-time PCR. f FoxP3 mRNA was notably increased in response to IL-35 stimulation in both CHB and ASC. g RORγt mRNA did not change significantly in response to IL-35 stimulation in either CHB or ASC. Individual level for each subject was presented, and comparisons were made using paired t tests. IL-10 and IL-17 production in cultured supernatants were measured by ELISA. h IL-10 expression in cultured supernatants was notably elevated in response to IL-35 stimulation in both CHB and ASC. i IL-17 expression in cultured supernatants was remarkably decreased in response to IL-35 stimulation only in CHB, but not in ASC. Individual level for each subject was presented, and comparisons were made using Wilcoxon matched pairs tests. Chronic HBV infection led to the imbalance between Tregs and Th17 cells, which mainly presented as the changes of percentage and function of both cell subsets in different disease stages. Imbalance of Tregs and Th17 cells played an important role in the occurrence, development and outcome of CHB [12, 22] . Feng et al. demonstrated both elevation of Tregs and Th17 cells, however, reduced ratio of Tregs/Th17 cells in chronic HBV infection, which were independent risk factors to hepatitis [23] . In contrast, some other studies reported that Treg cell levels decreased, while Th17 cell levels increased in peripheral blood of CHB patients [24, 25] . Tregs/Th17 imbalance was also associated with the survival and progression in HBV-associated liver cirrhosis [26, 27] and in acute-on-chronic hepatitis B liver failure [28, 29] . The imbalance between Tregs and Th17 cells served as a risk factor for HCC occurrence following cirrhosis [13, 30] . Restoring the Tregs to Th17 cell ratio might maintained immune system at a steady state, which alleviated liver injury in HBV-related acute-onchronic liver failure [31] . However, few studies focused on viral specific Tregs/Th17 cells imbalance during HBV infection. To the best of our knowledge, we firstly revealed an imbalance of HBV core-specific CD4 + CD25 + CD127 dim/ − Tregs and Th17 cells in CHB patients, which presented as increased viral specific Th17 frequency but comparable viral specific Tregs percentage between CHB and ASC. Moreover, previous reports also indicated sustained changes of Tregs/Th17 cells and their related cytokines were closely related to virological, biochemical, and serological responses to nucleos(t)ide analogues (including entecavir, lamivudine, adefovir, and telbivudine) [32] [33] [34] and interferon-α therapy [35] . However, we found that effective anti-HBV therapy by Individual level for each subject was presented, and comparisons were made using paired t tests TDF did not restore the imbalance between HBV core-specific Tregs and Th17 cells three months post initiation of treatment. This might be partly due to the relatively short followed-up period. Further experiments were needed for investigating the changes of viral specific Tregs/Th17 imbalance in CHB patients with long-term administration of anti-HBV drugs or with HBeAg seroconversion.
IL-35 functioned as an immunosuppressive factor in immune-mediated diseases. The predominant mechanism of suppression was to inhibit proliferation and effector activities of T cells, thus, might be a potential therapeutic target for controlling HBV infection [19] . Both serum IL-35 and IL-35 mRNA in CD4 + T cells was elevated in chronic HBV infection, and was associated with viral replication and hepatocytes damage [36, 37] . Recombinant IL-35 stimulation not only directly increased HBV transcription and replication in vivo [38] , but also suppressed HBV core-specific interferon-γ-secreting CD8 + T cells in vitro [39] . Our previous study also indicated an immunosuppressive activity of IL-35 in chronic HBV infection [17] . The elevated IL-35 in CHB and ASC enhanced suppressive function of CD4 + CD25 + CD127 dim/− Tregs, while reduced cytolytic and noncytolytic activity of HBV antigen-specific CD8 + T cells, which might due to the direct response and positive feedback mechanisms of Tregs to IL-35 [17] . IL-35 was shown to mitigate the function of murine transplanted islet cells via regulation of the Treg/Th17 ratio [40] . In enterovirus 71-induced hand, foot, and mouth disease, recombinant IL-35 directly modulated Tregs/Th17 imbalance [18] . [41] and hemocytopenia [42] , in which Th17 cells was strongly inhibited by delivery of IL-35. This might be partly due to the difference status of chronic and acute viral infections. Moreover, we also found that IL-35 treatment partly restored the imbalance of HBV core-specific Tregs and Th17 cells in CHB patients, however, ratio of viral specific Tregs/Th17 cells in CHB patients was still lower than that in ASC in response to IL-35 stimulation.
Antigen stimulation and/or pathogen infections could induce IL-17 production by CD4 + FoxP3 + Tregs [43] . The CD4 + RORγt + FoxP3 + T cells represented intermediates during Tregs/Th17 transdifferentiation, and constituted an independent biofunctional regulatory cell lineage which contributed to cresecentic glomerulonephritis [44] . Toll-like receptor 2 (TLR2) signaling promoted IL-17 production in Tregs during oropharyngeal candidiasis [45] and HCV infection [21] . The current data revealed that IL-35 stimulation inhibited the differentiation of HBV core-specific Tregs into a Th17-like phenotype by dampening IL-17/IL-22 production and reducing CCR4/ CCR6 expression. Furthermore, effective inhibition of HBV replication by TDF induced the decreased CD4 + CD25 + CD127 dim/− Tregs and Th17 cell responsiveness to IL-35 in CHB patients. This was consistent with the reduced responsiveness of Tregs/Th17 to TLR2 in chronic HCV infected patients with direct-acting antiviral drugs therapy [46] . This might imply that chronic HBV infection might increase the responsiveness of CD4 There were limitations of the current study. Firstly, the experiments were solely performed on PBMC due to the limited HLA-A2 restricted patients enrolled. A large number of cases could be analyzed in order to obtained a suitable statistic number to compare. Secondly, cells in the peripheral blood do not accurately represented the intra-hepatic environment. Thus, further in vivo experiments or purified lymphocytes from liver biopsy samples were needed to confirm the in vitro results.
Conclusion
In summary, we demonstrated that IL-35 modulated viral specific Tregs/Th17 cell balance in patients with 
